Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Ascending Multiple-Dose Study of the Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Chronic Hepatitis C Infection

NCT00782353 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00782353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00782353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Ascending Multiple-Dose Study of the Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Chronic Hepatitis C Infection
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2008
Completion date
March 31, 2009
Enrollment
35 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c